Erasca Inc
Cerrado
18.1
Resumen
Variación precio
24h
Mínimo
17.68
Máximo
18.48
Ingresos | 139M -44M |
|---|---|
BPA | -0.14 |
Empleados | 103 |
EBITDA | 139M -43M |
Recomendaciones | Comprar |
|---|---|
Estimación a 12 Meses | +26.3% upside |
Próximas Ganancias | 10 nov 2026 |
|---|
Capitalización Mercado | 104M 6.4B |
|---|---|
Apertura anterior | 18.1 |
Cierre anterior | 18.1 |
Erasca Inc Gráfico
Resultados pasados no son un indicador fiable de resultados futuros.
Noticias Relacionadas
Comparación entre iguales
Cambio de precio
Erasca Inc previsión
Precio Objetivo
By TipRanks
26.3% repunte
Estimación a 12 Meses
Media 22.86 USD 26.3%
Máximo 30 USD
Mínimo 20 USD
De acuerdo con 7 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Erasca Inc Dist en los últimos 3 meses.
Finanzas
Gastos de venta y administración
Gastos operativos
Beneficio antes de impuestos
Ventas
Coste de ventas
Beneficio bruto de ventas
Gasto por intereses de deuda
EBITDA
Beneficio operativo
$
Acerca de Erasca Inc
Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.